Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 7, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study looks at how often patients being treated for non-Hodgkin lymphoma develop pneumonitis, a swelling of the lungs. The study concluded that patients being treated with R-CDOP chemotherapy are at the highest risk of developing pneumonitis. 

Some background

Pneumonitis is a dangerous and potentially deadly swelling of the lungs and lung tissue. Pneumonitis is a rare side effect of chemotherapy treatment. Some chemotherapy treatments that include doxorubicin and/or rituximab may cause pneumonitis. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (plus rituximab), CDOP (cyclophosphamide, pegylated liposomal doxorubicin, vincristine, prednisone) and R-CDOP (plus rituximab) are some chemotherapies that may lead to pneumonitis.

More research is needed to determine which chemotherapies have the greatest risk of causing pneumonitis. 

Methods & findings

The medical records of 207 patients were reviewed. 89 patients received CHOP. 57 patients received R-CHOP. 23 patients received CDOP. 38 patients received R-CDOP.

13 patients developed pneumonitis. No patients in the CHOP group developed pneumonitis. One patient (1.8%) in the R-CHOP group developed pneumonitis. Four patients (17.4%) in the CDOP group developed pneumonitis. Eight patients (21.1%) in the R-CDOP group developed pneumonitis.

Significantly more patients in the CDOP and R-CDOP groups developed pneumonitis compared to patients in the CHOP and R-CHOP groups. Additionally, the pneumonitis was worse on average in the R-CDOP group.

Another risk factor for developing pneumonitis was having a significant shortage of neutrophils (a type of white blood cell), called neutropenia (grade 4). 

The bottom line

The authors concluded that patients with non-Hodgkin lymphoma treated with R-CDOP chemotherapy are at a higher risk of developing pneumonitis compared to other chemotherapy treatments, and neutropenia is also a risk factor. 

Published By :

Annals of Hematology

Date :

Oct 31, 2017

Original Title :

Incidence of interstitial pneumonitis in non-Hodgkin’s lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.

click here to get personalized updates